A clinical trial of prostaglandin E2 to increase erythropoiesis in anemia of end stage renal disease. A preliminary report
| Autor: | Nomie A. Shore, Jorge A. Ortega, Malekzadeh Mh, Andrew Ma, Peter P. Dukes |
|---|---|
| Rok vydání: | 1984 |
| Předmět: |
Male
medicine.medical_specialty Time Factors Adolescent Physiology Anemia medicine.medical_treatment Stimulation Biochemistry Dinoprostone End stage renal disease Endocrinology hemic and lymphatic diseases Internal medicine medicine Humans Erythropoiesis Prostaglandin E2 Clinical Trials as Topic Chemotherapy business.industry Prostaglandins E medicine.disease Clinical trial Vomiting Kidney Failure Chronic medicine.symptom business medicine.drug |
| Zdroj: | Prostaglandins, Leukotrienes and Medicine. 14:411-416 |
| ISSN: | 0262-1746 |
| DOI: | 10.1016/0262-1746(84)90124-0 |
| Popis: | Prostaglandin E2 is known to stimulate erythropoiesis by different mechanisms. A clinical trial of prostaglandin E2 to stimulate erythropoiesis in four patients with anemia of end stage renal disease resulted in an increment in peripheral blood Burst Forming Units-Erythroid (BFU-E). This increase in erythroid progenitors returned to baseline with cessation of therapy. A significant increase in serum erythropoietin (EPO) activity was demonstrated in one patient and was noticeable in another. Side effects mainly consisted of local pain at the site of the infusion and vomiting. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|